Latest News

Genetic evidence that new therapies targeting Parkinson's disease may cause harm

Researchers have completed a small study that shows genetic and clinical evidence that therapies targeting the expression of alpha-synuclein -- a gene whose function is involved in the development and progression of Parkinson?s disease -- may accelerate disease progression and increase the risk of physical incapacitation and dementia. If replicated, the findings will have profound implications for therapies under development for Parkinson?s disease.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Commonly available blood-pressure medication prevents epilepsy after severe brain injury

  • Critical new protein complex involved in learning, memory

  • Teachers' scare tactics may lead to lower exam scores

  • Financial incentives help economically-disadvantaged pregnant smokers quit, improve fetal growth

  • Regulating legal marijuana could be guided by lessons from alcohol, tobacco, study says

  • Want to quit smoking? New study says try 'self-expanding' activities

  • Mentor programs harm, more than help first-year teachers

  • Physicists push new Parkinson's treatment toward clinical trials

  • First brain images of African infants enable research into cognitive effects of nutrition

  • New way to enhance nerve growth following injury discovered

  •